These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 34004140)

  • 21. Adaptive immune responses to booster vaccination against yellow fever virus are much reduced compared to those after primary vaccination.
    Kongsgaard M; Bassi MR; Rasmussen M; Skjødt K; Thybo S; Gabriel M; Hansen MB; Christensen JP; Thomsen AR; Buus S; Stryhn A
    Sci Rep; 2017 Apr; 7(1):662. PubMed ID: 28386132
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparing immunogenicity and protective efficacy of the yellow fever 17D vaccine in mice.
    Ma J; Boudewijns R; Sanchez-Felipe L; Mishra N; Vercruysse T; Buh Kum D; Thibaut HJ; Neyts J; Dallmeier K
    Emerg Microbes Infect; 2021 Dec; 10(1):2279-2290. PubMed ID: 34792431
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development of a hydrogen peroxide-inactivated vaccine that protects against viscerotropic yellow fever in a non-human primate model.
    Amanna IJ; Thomas A; Engelmann F; Hammarlund E; Raué HP; Bailey AL; Poore EA; Quintel BK; Lewis AD; Axthelm MK; Johnson AL; Colgin LMA; Diamond MS; Messaoudi I; Slifka MK
    Cell Rep Med; 2024 Jul; 5(7):101655. PubMed ID: 39019010
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Characterization of Yellow Fever Virus Infection of Human and Non-human Primate Antigen Presenting Cells and Their Interaction with CD4+ T Cells.
    Cong Y; McArthur MA; Cohen M; Jahrling PB; Janosko KB; Josleyn N; Kang K; Zhang T; Holbrook MR
    PLoS Negl Trop Dis; 2016 May; 10(5):e0004709. PubMed ID: 27191161
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Vaccination with Replication Deficient Adenovectors Encoding YF-17D Antigens Induces Long-Lasting Protection from Severe Yellow Fever Virus Infection in Mice.
    Bassi MR; Larsen MA; Kongsgaard M; Rasmussen M; Buus S; Stryhn A; Thomsen AR; Christensen JP
    PLoS Negl Trop Dis; 2016 Feb; 10(2):e0004464. PubMed ID: 26886513
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 17D yellow fever vaccine elicits comparable long-term immune responses in healthy individuals and immune-compromised patients.
    Wieten RW; Goorhuis A; Jonker EFF; de Bree GJ; de Visser AW; van Genderen PJJ; Remmerswaal EBM; Ten Berge IJM; Visser LG; Grobusch MP; van Leeuwen EMM
    J Infect; 2016 Jun; 72(6):713-722. PubMed ID: 27017899
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Short-Lived Immunity After 17DD Yellow Fever Single Dose Indicates That Booster Vaccination May Be Required to Guarantee Protective Immunity in Children.
    Campi-Azevedo AC; Reis LR; Peruhype-Magalhães V; Coelho-Dos-Reis JG; Antonelli LR; Fonseca CT; Costa-Pereira C; Souza-Fagundes EM; da Costa-Rocha IA; Mambrini JVM; Lemos JAC; Ribeiro JGL; Caldas IR; Camacho LAB; Maia MLS; de Noronha TG; de Lima SMB; Simões M; Freire MDS; Martins RM; Homma A; Tauil PL; Vasconcelos PFC; Romano APM; Domingues CM; Teixeira-Carvalho A; Martins-Filho OA
    Front Immunol; 2019; 10():2192. PubMed ID: 31616412
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Type III Interferon-Mediated Signaling Is Critical for Controlling Live Attenuated Yellow Fever Virus Infection
    Douam F; Soto Albrecht YE; Hrebikova G; Sadimin E; Davidson C; Kotenko SV; Ploss A
    mBio; 2017 Aug; 8(4):. PubMed ID: 28811340
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Plasmid DNA initiates replication of yellow fever vaccine in vitro and elicits virus-specific immune response in mice.
    Tretyakova I; Nickols B; Hidajat R; Jokinen J; Lukashevich IS; Pushko P
    Virology; 2014 Nov; 468-470():28-35. PubMed ID: 25129436
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CD8+ T cells complement antibodies in protecting against yellow fever virus.
    Bassi MR; Kongsgaard M; Steffensen MA; Fenger C; Rasmussen M; Skjødt K; Finsen B; Stryhn A; Buus S; Christensen JP; Thomsen AR
    J Immunol; 2015 Feb; 194(3):1141-53. PubMed ID: 25539816
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dependence of CD8 T Cell Response upon Antigen Load During Primary Infection : Analysis of Data from Yellow Fever Vaccination.
    Moore JR; Ahmed H; McGuire D; Akondy R; Ahmed R; Antia R
    Bull Math Biol; 2019 Jul; 81(7):2553-2568. PubMed ID: 31165405
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Primary and secondary anti-viral response captured by the dynamics and phenotype of individual T cell clones.
    Minervina AA; Pogorelyy MV; Komech EA; Karnaukhov VK; Bacher P; Rosati E; Franke A; Chudakov DM; Mamedov IZ; Lebedev YB; Mora T; Walczak AM
    Elife; 2020 Feb; 9():. PubMed ID: 32081129
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of safety and immuno-efficacy of a next generation live-attenuated yellow fever vaccine in cynomolgus macaques.
    Piras-Douce F; Broudic K; Chautard E; Raynal F; Courtois V; Gautheron S; Mantel N
    Vaccine; 2023 Feb; 41(8):1457-1470. PubMed ID: 36702693
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immune activation alters cellular and humoral responses to yellow fever 17D vaccine.
    Muyanja E; Ssemaganda A; Ngauv P; Cubas R; Perrin H; Srinivasan D; Canderan G; Lawson B; Kopycinski J; Graham AS; Rowe DK; Smith MJ; Isern S; Michael S; Silvestri G; Vanderford TH; Castro E; Pantaleo G; Singer J; Gillmour J; Kiwanuka N; Nanvubya A; Schmidt C; Birungi J; Cox J; Haddad EK; Kaleebu P; Fast P; Sekaly RP; Trautmann L; Gaucher D
    J Clin Invest; 2014 Jul; 124(7):3147-58. PubMed ID: 24911151
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical evidence for the immunogenicity and immune persistence of vaccination with yellow fever virus strain 17D in Chinese peacekeepers deployed to Africa.
    Jia Q; Jia C; Liu Y; Yang Y; Qi J; Tong L; Chen H; Zhang M; Che J; Li B; Li Z
    Antiviral Res; 2019 Feb; 162():1-4. PubMed ID: 30529359
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pathophysiologic and transcriptomic analyses of viscerotropic yellow fever in a rhesus macaque model.
    Engelmann F; Josset L; Girke T; Park B; Barron A; Dewane J; Hammarlund E; Lewis A; Axthelm MK; Slifka MK; Messaoudi I
    PLoS Negl Trop Dis; 2014; 8(11):e3295. PubMed ID: 25412185
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Chimeric Japanese Encephalitis Vaccine Protects against Lethal Yellow Fever Virus Infection without Inducing Neutralizing Antibodies.
    Mishra N; Boudewijns R; Schmid MA; Marques RE; Sharma S; Neyts J; Dallmeier K
    mBio; 2020 Apr; 11(2):. PubMed ID: 32265332
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 17DD Yellow Fever Revaccination and Heightened Long-Term Immunity in Populations of Disease-Endemic Areas, Brazil.
    Campi-Azevedo AC; Peruhype-Magalhāes V; Coelho-Dos-Reis JG; Antonelli LR; Costa-Pereira C; Speziali E; Reis LR; Lemos JA; Ribeiro JGL; Bastos Camacho LA; de Sousa Maia ML; Barbosa de Lima SM; Simões M; de Menezes Martins R; Homma A; Cota Malaquias LC; Tauil PL; Costa Vasconcelos PF; Martins Romano AP; Domingues CM; Teixeira-Carvalho A; Martins-Filho OA;
    Emerg Infect Dis; 2019 Aug; 25(8):1511-1521. PubMed ID: 31298654
    [TBL] [Abstract][Full Text] [Related]  

  • 39. New approaches for the standardization and validation of a real-time qPCR assay using TaqMan probes for quantification of yellow fever virus on clinical samples with high quality parameters.
    Fernandes-Monteiro AG; Trindade GF; Yamamura AM; Moreira OC; de Paula VS; Duarte AC; Britto C; Lima SM
    Hum Vaccin Immunother; 2015; 11(7):1865-71. PubMed ID: 26011746
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Yellow fever virus 17D envelope and NS3 proteins are major targets of the antiviral T cell response in mice.
    van der Most RG; Harrington LE; Giuggio V; Mahar PL; Ahmed R
    Virology; 2002 Apr; 296(1):117-24. PubMed ID: 12036323
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.